Stocks Comparison
Immucell vs QuidelOrtho: revenue, profit, margins and growth compared
Immucell brought in $27.6M of revenue in fiscal 2025, QuidelOrtho $2.7B in fiscal 2025. Revenue changed by +4.3% at Immucell and -1.9% at QuidelOrtho on the year before, so Immucell grew faster. Immucell kept -3.8% of its revenue as net profit, QuidelOrtho -41.5%. Free cash flow was $1.2M at Immucell and -$83M at QuidelOrtho.
Side by side, latest fiscal year
| ICCC | QDEL | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 28, 2025) |
| Revenue | $27.6M | $2.7B |
| Revenue growth | +4.3% | -1.9% |
| Net income | -$1M | -$1.1B |
| Net margin | -3.8% | -41.5% |
| Free cash flow | $1.2M | -$83M |
| Free cash flow margin | 4.4% | -3.0% |
| Earnings per share (diluted) | -$0.12 | -$16.69 |
| Cash | $3.8M | $169.8M |
| Debt | $9.1M | $2.7B |
| Price to earnings | n/a | n/a |
| Market value | $90.1M | $750.2M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #396 of 523 · Health care | #90 of 523 · Health care |
Over the years
Questions about Immucell and QuidelOrtho
Which is bigger by revenue, Immucell or QuidelOrtho?
QuidelOrtho is bigger by revenue: $2.7B in fiscal 2025, against $27.6M for Immucell in fiscal 2025.
Which keeps more of its revenue as profit, Immucell or QuidelOrtho?
Immucell had a net margin of -3.8% in fiscal 2025; QuidelOrtho had -41.5% in fiscal 2025.
Which grew revenue faster, Immucell or QuidelOrtho?
In their latest fiscal years revenue changed by +4.3% at Immucell and -1.9% at QuidelOrtho.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.